Literature DB >> 9482107

Transformation suppressor activity of C3G is independent of its CDC25-homology domain.

C Guerrero1, A Fernandez-Medarde, J M Rojas, J Font de Mora, L M Esteban, E Santos.   

Abstract

The guanine nucleotide releasing protein C3G was initially identified as a Crk SH3-binding protein and recently shown to exhibit exchange activity on Rap1 proteins. Overexpression in NIH3T3 cells of a full-length C3G cDNA isolated from human placenta markedly reduced the focus forming activity of cotransfected, malignantly activated, ras oncogenes (5-7-fold). C3G also had a reverting effect on sis-mediated transformation, decreasing the number of c-sis-induced foci by a factor of 5-10-fold. The observed inhibitory effect of C3G on focus-forming activity of Ras and Sis was always higher than that observed with Rap1A, a known target of C3G. The inhibition of focus formation observed in the presence of C3G was not due to toxic effects on cell viability, since transfected C3G cells exhibited the same survival and growth rates as untransfected NIH3T3 cells or cells transfected with plasmid vector alone. Surprisingly, as opposed to Rap1A, which has no effect on Raf-1 oncogene-mediated transformation, C3G also reduced dramatically (6-8-fold) the number of v-raf-induced foci in transfected NIH3T3 cells. The inhibitory effect on Raf-induced transformation suggests that C3G has other functional targets in addition to Rap1. A C3G mutant (C3G deltaCat) lacking the catalytic domain (CDC25-H) but retaining the rest of the N-terminal sequences, including the Crk-binding domain, exhibited similar ability than full length C3G to inhibit focus formation. In contrast, a C3G mutant (C3G Cat), containing the catalytic domain only but lacking the rest of the N-terminal sequences, did not have any inhibitory effect on transformation mediated by the oncogenes tested. The C3G-derived gene products overexpressed in our transfected cell lines localized to the cytoplasm and did not change the basal MAPK or JNK activity of those cell lines nor their ability to activate the kinases in response to agonists. Our results suggest that the N-terminal region of C3G, and not its catalytic domain, may be responsible for the inhibitory effects observed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482107     DOI: 10.1038/sj.onc.1201569

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  C3G contributes to platelet activation and aggregation by regulating major signaling pathways.

Authors:  Cristina Fernández-Infante; Luis Hernández-Cano; Sara Gutiérrez-Herrero; Sara Ortiz-Rivero; Carlos Guijas; Víctor Martín-Granado; José Ramón González-Porras; Jesús Balsinde; Almudena Porras; Carmen Guerrero
Journal:  Signal Transduct Target Ther       Date:  2020-04-01

2.  Reciprocal Negative Regulation between the Guanine Nucleotide Exchange Factor C3G and β-Catenin.

Authors:  Kunal Dayma; Anesh Ramadhas; Kotagiri Sasikumar; Vegesna Radha
Journal:  Genes Cancer       Date:  2012-09

3.  C3G shows regulated nucleocytoplasmic exchange and represses histone modifications associated with euchromatin.

Authors:  Dhruv Kumar Shakyawar; Kunal Dayma; Anesh Ramadhas; Chavvakula Varalakshmi; Vegesna Radha
Journal:  Mol Biol Cell       Date:  2017-02-01       Impact factor: 4.138

4.  C3G, through its GEF activity, induces megakaryocytic differentiation and proplatelet formation.

Authors:  Sara Ortiz-Rivero; Cristina Baquero; Luis Hernández-Cano; Juan José Roldán-Etcheverry; Sara Gutiérrez-Herrero; Cristina Fernández-Infante; Víctor Martín-Granado; Eduardo Anguita; José María de Pereda; Almudena Porras; Carmen Guerrero
Journal:  Cell Commun Signal       Date:  2018-12-19       Impact factor: 5.712

5.  C3G forms complexes with Bcr-Abl and p38α MAPK at the focal adhesions in chronic myeloid leukemia cells: implication in the regulation of leukemic cell adhesion.

Authors:  Vera Maia; Sara Ortiz-Rivero; María Sanz; Javier Gutierrez-Berzal; Indira Alvarez-Fernández; Sara Gutierrez-Herrero; Jose María de Pereda; Almudena Porras; Carmen Guerrero
Journal:  Cell Commun Signal       Date:  2013-01-23       Impact factor: 5.712

6.  FISH mapping of Philadelphia negative BCR/ABL1 positive CML.

Authors:  Anna Virgili; Diana Brazma; Alistair G Reid; Julie Howard-Reeves; Mikel Valgañón; Anastasios Chanalaris; Valeria As De Melo; David Marin; Jane F Apperley; Colin Grace; Ellie P Nacheva
Journal:  Mol Cytogenet       Date:  2008-07-18       Impact factor: 2.009

7.  Phosphorylated guanine nucleotide exchange factor C3G, induced by pervanadate and Src family kinases localizes to the Golgi and subcortical actin cytoskeleton.

Authors:  Vegesna Radha; Ajumeera Rajanna; Ghanshyam Swarup
Journal:  BMC Cell Biol       Date:  2004-08-20       Impact factor: 4.241

8.  C3G knock-down enhances migration and invasion by increasing Rap1-mediated p38α activation, while it impairs tumor growth through p38α-independent mechanisms.

Authors:  Neibla Priego; María Arechederra; Celia Sequera; Paloma Bragado; Ana Vázquez-Carballo; Álvaro Gutiérrez-Uzquiza; Víctor Martín-Granado; Juan José Ventura; Marcelo G Kazanietz; Carmen Guerrero; Almudena Porras
Journal:  Oncotarget       Date:  2016-07-19

9.  C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis.

Authors:  Víctor Martín-Granado; Sara Ortiz-Rivero; Rita Carmona; Sara Gutiérrez-Herrero; Mario Barrera; Laura San-Segundo; Celia Sequera; Pedro Perdiguero; Francisco Lozano; Francisco Martín-Herrero; José Ramón González-Porras; Ramón Muñoz-Chápuli; Almudena Porras; Carmen Guerrero
Journal:  Oncotarget       Date:  2017-11-06

Review 10.  How Rap and its GEFs control liver physiology and cancer development. C3G alterations in human hepatocarcinoma.

Authors:  Celia Sequera; Sara Manzano; Carmen Guerrero; Almudena Porras
Journal:  Hepat Oncol       Date:  2018-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.